Goldberg SB1, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, Mc Carthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. Erlotinib with or without hydroxychloroquine in chemo-naive advanced NSCLC and (EGFR) mutations. Boston, MA: National Library of Medicine (US): 2009-2015. Hydroxychloroquine skin rash treatment Chloroquine resistant malaria drug of choice Epidermal growth factor receptor tyrosine kinase inhibitors EGFR-TKIs, including gefitinib, are effective for non-small cell lung cancer NSCLC patients with EGFR mutations. However, these patients eventually develop resistance to EGFR-TKI. The goal of the present study was to investigate the involvement of autophagy in gefitinib resistance. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. Journal of Thoracic Oncology 86 693-702. Link here 2. The EGFR inhibitor erlotinib is much less effective in NSCLC tumors with wild-type EGFR than in tumors with activating EGFR mutations. Autophagy is a tightly regulated lysosomal self-digestion process that may alternatively promote cell survival or type. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Since the pivotal trial evaluating the effect of temozolomide (TMZ), overall survival has not increased. National Insitute of Health; Massachusetts General Hospital. Chloroquine egfr The Epidermal Growth Factor Receptor Antibody Cetuximab., Repurposing Drugs 101 - Chloroquine & Lung Cancer Chloroquine interactionHydroxychloroquine foods to avoidPlaquenil e pillola anticoncezionale The resistance to the EGFR-TKI involves activation of several pathways. One of the mechanisms depends on the appearance of secondary mutations in EGFR, such as Thr790Met, L858R or deletion of exon 19. Cell death-based treatment of lung adenocarcinoma. The autophagy inhibitor chloroquine overcomes the innate.. EGFRvIII expression triggers a metabolic dependency and therapeutic.. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Jun 28, 2017 The epidermal growth factor receptor EGFR and its associated pathway is a critical key regulator of CRC development and progression. The monoclonal antibodies MoAbs cetuximab and panitumumab, directed against EGFR, represent a major step forward in the treatment of metastatic colorectal cancer mCRC, in terms of progression-free survival and overall survival in several clinical trials.